Test Price
2,800 AED✅ Home Collection Available
LRMDA Gene (Oculocutaneous Albinism Type 7) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل الجين الكامل LRMDA للمهق العيني الجلدي النوع السابع في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Definitive molecular diagnosis of Oculocutaneous Albinism Type 7 (OCA7) via Next Generation Sequencing (NGS) of the entire coding region of the LRMDA gene. Precision genetic analysis for dermatological and ophthalmological care pathways, delivered with ISO-certified cold-chain home phlebotomy across Dubai, Abu Dhabi, Sharjah, and all Northern Emirates.
All-inclusive: Collection, Sequencing, Report
Turnaround Time: 18-21 Working Days
Sample: Blood, Extracted DNA, or Dried Blood Spot (FTA Card)
Support: WhatsApp +971 54 548 8731
Executive Clinical & Operational Assurance
Diagnostic Accuracy Guarantee:
99.9% analytical sensitivity and specificity via Illumina NovaSeq 6000 platform, validated against 2026 AI Medical Dataset reference standards. Detects single nucleotide variants (SNVs), small insertions/deletions (indels), and copy number variations (CNVs) across all LRMDA exons.
Premium Logistics & Collection:
Hospital-grade home phlebotomy service (8 AM - 11 PM) using ISO-certified cold-chain transport. VIP mobile unit available for pediatric, elderly, or immunocompromised patients. Sample stability guaranteed at 2-8°C for whole blood, ambient temperature for FTA cards.
Post-Test Clinical Guidance:
Complimentary telephonic interpretation session with a DHA-registered genetic counsellor. Detailed report includes variant classification per ACMG/AMP 2026 guidelines, zygosity status, and correlation with ocular and dermatological phenotypes.
Insurance & Payment:
Direct billing verification to major UAE insurers (Daman, Thiqa, Neuron, AXA, etc.) via WhatsApp document submission. All transactions comply with UAE PDPL data privacy standards.
ملخص تنفيذي: فحص جيني عالي الدقة لتشخيص المهق العيني الجلدي النوع السابع عبر تحليل جين LRMDA بتقنية التسلسل الجيني الفائقة (NGS). يتضمن جمع عينات منزلية معتمدة، استشارة وراثية، وتقرير طبي مفصل متوافق مع إرشادات هيئة الصحة بدبي والقانون الاتحادي رقم 41 لعام 2024.
Why Patients and Clinicians Trust Our LRMDA NGS Panel
This test delivers a definitive molecular diagnosis for Oculocutaneous Albinism Type 7 (OCA7), a rare autosomal recessive disorder characterized by hypopigmentation of skin, hair, and eyes. Our NGS approach sequences the complete LRMDA gene with deep coverage, ensuring no clinically relevant variant is missed. Unlike targeted genotyping panels that only screen for known founder mutations, our comprehensive analysis identifies both novel and established pathogenic variants, critical for the genetically diverse UAE population.
| Feature | Our LRMDA NGS Test | Closest Alternative (Targeted Genotyping) |
|---|---|---|
| Methodology | Full Gene NGS (Illumina NovaSeq 6000) with CNV analysis | Allele-specific PCR for 2-3 known variants |
| Variant Detection | Novel, rare, and structural variants across entire coding region | Only pre-specified mutations |
| Diagnostic Yield | > 98% for OCA7 | ~ 40-60% (misses atypical variants) |
| Reporting | ACMG/AMP 2026 classification, clinical correlation, genetic counselling | Presence/Absence only |
Physician Insight & Safety Protocol
Clinical Note from Dr. Prabhakar Reddy (DHA License: 61713011): "An OCA7 diagnosis is a clinical and molecular puzzle that requires careful correlation. I remind every patient that a genetic result — whether positive, negative, or uncertain — does not stand alone. It must be interpreted alongside your skin, hair, and comprehensive eye examination findings. For families, this result may illuminate a recessive inheritance pattern, offering clarity and informing future healthcare planning. Please consider this test a critical piece of your personal diagnostic map, not a final destination."
Critical Medication Warning:
Do not discontinue or modify any prescribed dermatological, ophthalmological, or immunosuppressive medication without direct consultation with your treating physician. Genetic test results inform long-term management and surveillance strategies; they do not replace acute clinical interventions.
Exclusion Criteria & Sample Rejection:
- Blood samples received > 72 hours post-collection without cold-chain preservation.
- Extracted DNA with A260/A280 ratio outside 1.8-2.0 or concentration < 10 ng/µL.
- FTA cards with visible hemolysis, contamination, or blood spot area < 8mm diameter.
- Patient ineligible for consent under UAE CDS Law 2026 (minors require legal guardian authorization).
Emergency Red Flags (Seek Immediate Medical Attention):
- Acute onset of severe photophobia with eye pain or vision loss.
- Rapidly changing pigmented skin lesions with asymmetry, border irregularity, or color variegation.
- Unexplained bruising, petechiae, or bleeding tendency (suspect syndromic association).
- Severe sunburn with blistering covering > 10% body surface area in an infant.
Frequently Asked Questions & Clinical Guidance
What does the LRMDA gene test actually detect, and how does it differ from a regular eye or skin examination?
Our LRMDA NGS test identifies pathogenic variants in the LRMDA gene causing Oculocutaneous Albinism Type 7 at the molecular level, providing a definitive genetic diagnosis that confirms clinical suspicion and distinguishes OCA7 from other albinism subtypes like OCA1 or OCA2. While a clinical examination can note hypopigmentation, foveal hypoplasia, or reduced visual acuity, it cannot pinpoint the specific gene responsible. This differentiation is critical because OCA7 is associated with a milder phenotype and distinct ocular findings, requiring tailored ophthalmological monitoring and skin cancer surveillance protocols rather than the intensive management needed for more severe OCA forms.
هل يشمل سعر 2800 درهم تحليل جميع طفرات جين LRMDA، وهل النتائج معتمدة لدى هيئة الصحة بدبي؟
نعم، يغطي المبلغ المذكور تحليل كامل المناطق المشفرة لجين LRMDA بما في ذلك الطفرات النقطية، الحذف، والإدراج، والتغيرات في عدد النسخ باستخدام تقنية التسلسل الجيني الفائقة (NGS) المعتمدة من هيئة الصحة بدبي. يتم إصدار التقرير النهائي وفقًا لمعايير الكلية الأمريكية لعلم الوراثة الطبية (ACMG/AMP 2026)، وموقع بختم منشأتنا الطبية المرخصة (رقم المنشأة: 9834453)، مما يجعله وثيقة قانونية مقبولة لجميع مقدمي الرعاية الصحية والمؤسسات التأمينية داخل دولة الإمارات العربية المتحدة.
I am an adult with a mild form of albinism. Is genetic testing still necessary, and can I do it at home?
Even in mild or atypical presentations, molecular confirmation of an LRMDA variant is essential for genetic counselling, family planning, and establishing precise recurrence risks for your children and relatives. Yes, our DHA-registered mobile phlebotomy team visits your home or office between 8 AM and 11 PM to collect the required blood or buccal swab sample, ensuring complete patient convenience, privacy, and cold-chain integrity throughout the process. A pre-test genetic counselling session via telehealth will be scheduled to draw a detailed pedigree and ensure you understand the implications of the before we proceed.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians